Use of luteolin in preparation of skin photoaging inhibitor

Abstract

The present application relates to the technical field of medicine, and in particular to the application of luteoloside in the preparation of skin photoaging inhibitor. Luteoloside can effectively reduce the oxidative stress reaction of skin cells induced by UVB irradiation, and inhibit the up-regulation of pro-inflammatory factor and aging-related gene expression. Luteoloside has clear application value in the preparation of drugs or functional products for improving skin photoaging, and can play a significant protective effect on the skin.

Description

Technical Field

[0001] This invention relates to the field of pharmaceutical technology, and more specifically, to the application of luteolin in the preparation of skin photoaging inhibitors. Background Technology

[0002] Photoaging is a phenomenon of skin aging or accelerated aging caused by long-term sun exposure. Skin exposed areas such as the face and neck will show characteristics such as increased wrinkles, roughness, and abnormal pigmentation. UVB acts on the keratinocytes of the skin epithelium, inducing DNA damage, mutation and cytokine release, leading to cell aging, inflammation and apoptosis.

[0003] Inhibiting cellular senescence can effectively improve problems such as UVB-induced photoaging of the skin.

[0004] Luteolin glycoside (CAS No.: 5373-11-5) is a natural flavonoid compound isolated from traditional Chinese medicinal herbs such as honeysuckle, forsythia, and chrysanthemum, which are known for their heat-clearing and detoxifying properties. While plants like honeysuckle, forsythia, and chrysanthemum possess certain anti-inflammatory and antioxidant effects, these effects primarily manifest under conditions of mechanical damage or chemical stimulation.

[0005] There are currently no studies on the anti-aging effects of luteolin on the skin. Summary of the Invention

[0006] The technical problem to be solved by the present invention is to provide the application of luteolin in the preparation of skin photoaging inhibitors.

[0007] The technical solution of the present invention to solve the above-mentioned technical problems is as follows: The present invention provides an in vitro inhibitor of skin cell aging factors, wherein the inhibitor includes luteolin.

[0008] Furthermore, aging factors include interleukin-6, interleukin-1β, TNF-α, and p53 regulatory protein.

[0009] Furthermore, the concentration of luteolin in the inhibitor is 50-100 μM.

[0010] This invention also provides the application of luteolin in the preparation of skin photoaging inhibitors.

[0011] The present invention also provides a skin photoaging inhibitor, the components of which include luteolin.

[0012] Furthermore, the skin photoaging inhibitor is a UVB-induced skin aging inhibitor.

[0013] Furthermore, the formulation is a pharmaceutical preparation; the dosage form of the pharmaceutical preparation includes tablets, granules, powders, capsules, oral liquids, emulsions, or injections, and its components also include other pharmaceutically acceptable excipients.

[0014] Furthermore, the preparation is a functional food; the types of functional foods include tea, powder, pills, paste, beverages, syrups, biscuits, candies or pastries, and their ingredients also include other food science acceptable excipients.

[0015] The beneficial effects of this invention are as follows: Luteolin can effectively reduce UVB-induced oxidative stress in skin cells, lower intracellular reactive oxygen species levels, and in a concentration-dependent manner inhibit the upregulation of UVB-induced pro-inflammatory factors TNF-α, IL-1β, IL-6, and the aging-related gene p53 mRNA expression.

[0016] In summary, luteolin has clear application value in the preparation of anti-aging drugs or functional products for the skin, and can play a protective role against photoaging of the skin. Attached Figure Description

[0017] Figure 1 In this embodiment of the invention, the fluorescence staining of ROS levels in immortalized keratinocytes in each group is shown. Crtl is the control group, UVB is the UVB radiation group (i.e., the model group), UVB+LUT-7G is the luteolin intervention group, and LUT-7G is the luteolin control group.

[0018] Figure 2 This is a comparison chart of ROS levels in each group of immortalized keratinocytes, as shown in an embodiment of the present invention. Figure 3 This is a comparison of IL-β mRNA expression levels in different groups of immortalized keratinocytes, as shown in an embodiment of the present invention. Figure 4 This is a comparison of IL-6 mRNA expression levels in immortalized keratinocytes from different groups, as shown in an embodiment of the present invention. Figure 5 This is a comparison of TNF-α expression levels in different groups of immortalized keratinocytes, as shown in an embodiment of the present invention. Figure 6 This is a comparison of the expression levels of p53 mRNA, a gene related to senescence in immortalized keratinocytes, in various embodiments of the present invention. Detailed Implementation

[0019] The principles and features of the present invention are described below. The examples given are only for explaining the present invention and are not intended to limit the scope of the present invention.

[0020] The in vitro inhibitor of skin cell aging factors of the present invention includes luteolin as a component.

[0021] The structural formula of luteolin-7-O-glucoside is shown in Formula I.

[0022] Formula I For skin cells, UVB irradiation can significantly induce an increase in intracellular ROS levels. This invention experimentally demonstrates that luteolin exhibits significant antioxidant activity in an immortalized keratinocyte (HaCaT) photoaging model, and the expression of key inflammatory factors (TNF-α, IL-1β, IL-6) and the aging-related gene p53 mRNA in HaCaT cells is inhibited by luteolin.

[0023] Preferably, the concentration of luteolin in the in vitro inhibitor of skin cell aging factors is 50-100 μM.

[0024] Based on the above mechanism, the in vitro inhibitor of skin cell aging factors of the present invention can significantly inhibit the aging of HaCaT cells.

[0025] Therefore, luteolin can be used to prepare skin photoaging inhibitors.

[0026] The skin photoaging inhibitor of the present invention includes luteolin as a component; further, the skin photoaging inhibitor is a UVB-induced skin aging inhibitor.

[0027] The formulations of the present invention can be pharmaceuticals, and the dosage forms of the pharmaceuticals include tablets, granules, powders, capsules, oral liquids, emulsions or injections, and their components also include other pharmaceutically acceptable excipients.

[0028] In pharmaceutical preparations, prohibited / not recommended ingredients include: strong alkaline compounds, strong oxidizing substances, heavy metal ion preparations, high-concentration alcohol solubilizers (>50%), and tannins and alkaloids that can complex / degrade with luteolin, in order to avoid reducing the content of active ingredients, affecting efficacy, or causing adverse reactions.

[0029] The formulations of the present invention can also be functional foods; their types include teas, powders, pills, ointments, beverages, syrups, biscuits, candies, or pastries, and their ingredients also include other food science-acceptable excipients.

[0030] In functional foods, prohibited / not recommended ingredients include: high-alkaline food additives, strong oxidants (such as benzoyl peroxide), high-concentration alcohol, and ingredients that may damage the structure of luteolin or antagonize its efficacy, in order to ensure stable product efficacy and safety compliance.

[0031] The beneficial effects of the present invention will be illustrated by specific embodiments below.

[0032] Example: Effects of luteolin on UVB-induced skin cell aging and inflammation In this embodiment, immortalized keratinocytes (HaCaT) were selected to establish a photoaging cell model, and UVB irradiation (60 mJ / cm²) was detected by qRT-PCR. 2 The effects of different concentrations of luteolin on the expression of key inflammatory factors (TNF-α, IL-1β, IL-6) and aging-related gene p53 mRNA in HaCaT cells.

[0033] Specifically, the experiment in this embodiment set up a control group (Ctrl) and a model group (UVB irradiation (60 mJ / cm²)). 2 The study included luteolin treatment groups with different concentrations of luteolin, all of which were pretreated with LUT-7G. The luteolin concentrations in each treatment group were 10 μM, 50 μM, and 100 μM, respectively.

[0034] Test results as follows Figure 1-6 As shown.

[0035] UVB irradiation significantly induces an increase in intracellular ROS levels. Pretreatment with LUT-7G effectively alleviates this oxidative stress response, and luteolin intervention exhibits significant antioxidant activity. Specifically, such as... Figure 1 and 2 As shown, compared with the model group, the luteolin treatment groups at all concentrations significantly reduced the level of ROS, and luteolin inhibited its upregulation in a concentration-dependent manner, and restored its expression to near the baseline level at 100 μM.

[0036] UVB irradiation also significantly induced the expression of genes related to key inflammatory factors (TNF-α, IL-1β, IL-6), and the expression of these genes was inhibited after treatment with luteolin. Figure 3-5 As shown, at concentrations of 50 μM and 100 μM, luteolin intervention significantly inhibited the expression of IL-1β mRNA, IL-6 mRNA, and TNF-α mRNA.

[0037] UVB irradiation also significantly induced the expression level of the aging-related gene p53 mRNA, and the expression level of p53 mRNA was also inhibited after treatment with luteolin. Figure 6 As shown, at concentrations of 50 μM and 100 μM, luteolin significantly inhibited the expression of p53 mRNA.

[0038] In summary, luteolin can significantly reduce skin inflammation and photoaging caused by UVB irradiation in vitro, and has significant anti-inflammatory and potential anti-cellular aging activities.

[0039] Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention. Those skilled in the art can make changes, modifications, substitutions and variations to the above embodiments within the scope of the present invention.

Claims

1. An in vitro inhibitor of skin cell aging factors, characterized in that, The inhibitors include luteolin.

2. The in vitro inhibitor of mRNA expression of skin cell aging factors according to claim 1, characterized in that, The aging factors include interleukin-6, interleukin-1β, TNF-α, and p53 regulatory protein.

3. The in vitro inhibitor of mRNA expression of skin cell aging factors according to claim 2, characterized in that, The concentration of luteolin in the inhibitor is 50-100 μM.

4. Application of luteolin in the preparation of skin photoaging inhibitors.

5. A skin photoaging inhibitor, characterized in that, Its components include luteolin.

6. A skin photoaging inhibitor according to claim 5, characterized in that, The skin photoaging inhibitor is a UVB-induced skin aging inhibitor.

7. A skin photoaging inhibitor according to claim 6, characterized in that, The preparation is a pharmaceutical preparation; the dosage form of the pharmaceutical preparation includes tablets, granules, powders, capsules, oral liquids, emulsions or injections, and its components also include other pharmaceutically acceptable excipients.

8. A skin photoaging inhibitor according to claim 6, characterized in that, The preparation is a functional food; the types of functional foods include tea, powder, pills, paste, beverages, syrups, biscuits, candies or pastries, and their ingredients also include other food science acceptable excipients.

Images